Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.2300 +0.0063 (+2.82%)
Official Closing Price Updated: 6:30 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 471,076
Open 0.2344
Bid (Size) 0.2212 (1)
Ask (Size) 0.2286 (1)
Prev. Close 0.2237
Today's Range 0.2220 - 0.2344
52wk Range 0.2027 - 3.890
Shares Outstanding 31,792,580
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter
Via Investor Brand Network
Could Wheat Germ Hold the Key to Supercharging Immunotherapy? New Research Hopes to Find Out
Via Investor Brand Network

Performance

YTD
-80.5%
-80.5%
1 Month
-34.3%
-34.3%
3 Month
-59.4%
-59.4%
6 Month
-81.1%
-81.1%
1 Year
-88.1%
-88.1%

More News

Read More
Top movers in Monday's after hours session
Via Chartmill
Study Explains Why Most Smokers Never Get to Develop Lung Cancer
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth
Via Investor Brand Network
Celebrity Announcements of Breast Cancer Underscore Increasing Prevalence in Younger Women
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Korean Researchers Develop AI to Predict Cancer Patients’ Response to Immunotherapy
Via Investor Brand Network
Topics Artificial Intelligence
University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO
Via Investor Brand Network
New Multimodal AI System Boosts the Accuracy of Lung Cancer Screening
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses
Via Investor Brand Network
Getting a Second Opinion After Breast Cancer Diagnosis Doesn’t Delay Treatment Commencement
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment
Via Investor Brand Network
Study: Women with Lung Cancer Have Worse Outcomes Due to Genes Linked to Pregnancy
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
Via Investor Brand Network
Topics Death
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma
Via Investor Brand Network
How Stem Cells Help in Blood Cancer Treatment
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline
Via Investor Brand Network

Frequently Asked Questions

Is Calidi Biotherapeutics, Inc. Common Stock publicly traded?
Yes, Calidi Biotherapeutics, Inc. Common Stock is publicly traded.
What exchange does Calidi Biotherapeutics, Inc. Common Stock trade on?
Calidi Biotherapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Calidi Biotherapeutics, Inc. Common Stock?
The ticker symbol for Calidi Biotherapeutics, Inc. Common Stock is CLDI on the New York Stock Exchange
What is the current price of Calidi Biotherapeutics, Inc. Common Stock?
The current price of Calidi Biotherapeutics, Inc. Common Stock is 0.2300
When was Calidi Biotherapeutics, Inc. Common Stock last traded?
The last trade of Calidi Biotherapeutics, Inc. Common Stock was at 06/30/25 06:30 PM ET
What is the market capitalization of Calidi Biotherapeutics, Inc. Common Stock?
The market capitalization of Calidi Biotherapeutics, Inc. Common Stock is 7.31M
How many shares of Calidi Biotherapeutics, Inc. Common Stock are outstanding?
Calidi Biotherapeutics, Inc. Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.